Ad is loading...
MTISX
Price
$20.56
Change
-$0.13 (-0.63%)
Updated
Nov 15 closing price
RCEEX
Price
$71.49
Change
-$0.32 (-0.45%)
Updated
Nov 15 closing price
Ad is loading...

MTISX vs RCEEX

Header iconMTISX vs RCEEX Comparison
Open Charts MTISX vs RCEEXBanner chart's image
NYLI Income Builder SIMPLE Class
Price$20.56
Change-$0.13 (-0.63%)
VolumeN/A
CapitalizationN/A
American Funds Capital Income Bldr R2E
Price$71.49
Change-$0.32 (-0.45%)
VolumeN/A
CapitalizationN/A
MTISX vs RCEEX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MTISX vs. RCEEX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTISX is a StrongBuy and RCEEX is a Buy.

FUNDAMENTALS
Fundamentals
RCEEX has more cash in the bank: 107B vs. MTISX (1.05B). RCEEX pays higher dividends than MTISX: RCEEX (2.85) vs MTISX (2.66). MTISX was incepted earlier than RCEEX: MTISX (4 years) vs RCEEX (10 years). RCEEX is a more actively managed with annual turnover of: 106.00 vs. MTISX (56.00). RCEEX has a lower initial minimum investment than MTISX: RCEEX (250) vs MTISX (1000). MTISX annual gain was more profitable for investors over the last year : 20.16 vs. RCEEX (17.34).
MTISXRCEEXMTISX / RCEEX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence4 years10 years-
Gain YTD12.22910.184120%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets1.05B107B1%
Annual Yield % from dividends2.662.8594%
Returns for 1 year20.1617.34116%
Returns for 3 years0.9710.589%
Returns for 5 yearsN/A25.26-
Returns for 10 yearsN/A32.43-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TXNM46.300.49
+1.07%
TXNM Energy Inc
SBSI35.890.21
+0.59%
Southside Bancshares Inc
EML27.50-0.65
-2.31%
Eastern Company
CELH25.66-1.27
-4.72%
Celsius Holdings
CARA0.31-0.02
-5.04%
Cara Therapeutics